Tag: tumor lysis syndrome

Latest News

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Newsemia
Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva®...
Gastroenterology

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Newsemia
Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint. Source link...
Latest News

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

Newsemia
AbbVie, a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a...
Latest News

FDA expands label for VENCLEXTA to include information about patients with previously-treated CLL

Newsemia
AbbVie, a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration has expanded the label for VENCLEXTA® in combination with rituximab to...
Pharma / Biotech

TIBSOVO (Ivosidenib) Tablet, Film Coated [Agios Pharmaceuticals, Inc.]

Newsemia
Updated Date: Jul 24, 2018 EST...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World